Clinical trials: Progressive Supranuclear Palsy (PSP)
Parkinson's Disease, Progressive Supranuclear Palsy(PSP)
Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers
This research employs AI to analyze facial expressions and speech patterns, aiming to develop new digital tools for diagnosing and differentiating Parkinson's disease and similar disorders.
- Conditions
- Parkinson's Disease, Progressive Supranuclear Palsy(PSP), Multiple System Atrophy, Healthy Control
- Trial name
- NCT07392411
- Testing
- video recording
- Where
- China
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Parkinson's Disease, Alzheimer's Disease
Biomarkers in Neural Disorders
This study seeks to establish the sensitivity and specificity of what appears to be a unique brainstem biomarker of Parkinson's Disease (PD) - an electrically induced olygosynaptic nasotrigeminal reflex response - in…
- Conditions
- Parkinson's Disease, Alzheimer's Disease, Progressive Supranuclear Palsy, Essential Tremor
- Trial name
- NCT02761707
- Testing
- Electrical Brainstem Responses, Olfactory Tests, Visual Deprivation
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Parkinson Disease Dementia, Parkinson Disease
Community Outreach for Palliative Engagement -- Parkinson Disease
The purpose of this study is to learn more about the effectiveness of palliative care training for community physicians and telemedicine support services for patients and carepartners with Parkinson's disease and Lewy Body…
- Conditions
- Parkinson Disease Dementia, Parkinson Disease, Parkinson's Disease and Parkinsonism, Lewy Body Parkinsonism
- Trial name
- COPE-PD (NCT05222386)
- Testing
- Parkinson Disease Standard Care, Online Community-Supported Palliative Care
- Where
- United States
- Volunteers
- 632 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Parkinson Disease, Parkinson's Disease and Parkinsonism
Complex Eye Movements in Parkinson's Disease and Related Movement Disorders
Diagnosing Parkinson's disease (PD) depends on the clinical history of the patient and the patient's response to specific treatments such as levodopa.
- Conditions
- Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, Corticobasal Degeneration
- Trial name
- NCT04925622
- Testing
- Complex eye movement exam
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Saccadous, Inc.
Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS)
4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2
The goal of this study is to identify the most reliable methods of analysis for tracking CBD, PSP, and o/vPSP over time. The results from this study may be used in the future to calculate statistical power for clinical drug…
- Conditions
- Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), Cortical-basal Ganglionic Degeneration (CBGD), Progressive Supranuclear Palsy (PSP)
- Trial name
- 4RTNI-2 (NCT02966145)
- Testing
- Observational Study
- Where
- 8 sites in United States, Canada
- Volunteers
- 293 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Parkinsonian Syndrome, Parkinson Disease(PD)
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
This is a multicenter, open-label, non-controlled, non-randomized, phase 3 clinical study to compare the SPECT findings after a single IV administration of DaTSCAN™ ioflupane (123I) injection for patients with a clinical…
- Conditions
- Parkinsonian Syndrome, Parkinson Disease(PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP)
- Trial name
- NCT04193527
- Testing
- DaTSCAN™ Ioflupane (123I) Injection
- Where
- 10 sites in China
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Parkinson's Disease, Parkinson-Dementia Syndrome
Predictive and Diagnostic Value of Tau and Beta-amyloid Markers in the Dementia of Parkinson's Disease
The PET tracer Fluoro-ethyl-methyl-amino-naphthyl-ethylidene-malononitrile ([F18]-FDDNP) has a specific affinity for lesions containing tau protein and beta-amyloid The study consists of two phases In a first transversal phase, 8…
- Trial name
- NCT02243982
- Testing
- [F18]-FDDNP
- Where
- Spain
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Alzheimer Disease (AD), Frontotemporal Lobar Degeneration
ADDIA Proof-of-Performance Clinical Study
The objective of the ADDIA clinical Proof-of-Performance study is to validate the performance of ADDIA' blood biomarkers for diagnosis of Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease (AD), Frontotemporal Lobar Degeneration, Dementia with Lewy Bodies (DLB), Parkinson Disease Dementia (PDD)
- Trial name
- ADDIA (NCT03030586)
- Testing
- volumetric MRI
- Where
- 13 sites in Belgium, France and 3 more
- Volunteers
- 821 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Progressive Supranuclear Palsy, Multiple System Atrophy
NMR Based Metabolomic Study of Serum Biomarkers in Patients With Parkinson's Disease and Atypical Parkinsonian Syndrome
At present, the diagnosis of Parkinsons disease(PD) mainly relies on clinical symptoms and is easily confused with atypical Parkinsonian syndrome(APS) in the early stages. There is an urgent need for reliable biomarkers.
- Conditions
- Progressive Supranuclear Palsy, Multiple System Atrophy, Parkinson's Disease
- Trial name
- NCT06490926
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Fujian Medical University Union Hospital
Progressive Supranuclear Palsy
Risk Factors for Progressive Supranuclear Palsy (PSP)
Progressive supranuclear palsy (PSP) is the most common atypical parkinsonian movement disorder. This study will determine the role of specific genetic, occupational and environmental components in the development of PSP by…
- Trial name
- NCT00431301
- Where
- 10 sites in United States, Canada
- Volunteers
- 942 people, healthy volunteers welcome
- Sponsor
- University of Louisville
Progressive Supranuclear Palsy
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
This study is designed to learn more about overall tau burden in the brain of patients with Progressive Supranuclear Palsy (PSP).
- Trial name
- NCT02605785
- Testing
- F-18 AV 1451
- Where
- United States
- Volunteers
- 332 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Progressive Supranuclear Palsy, Alzheimer Disease
Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
The overall goal of this imaging trial is to evaluate [18F]MNI-952 (also known as [18F]UCB-K), a tau targeted PET radioligand.
- Conditions
- Progressive Supranuclear Palsy, Alzheimer Disease, Healthy Volunteers
- Trial name
- NCT03080051
- Testing
- [18F]MNI-952, [18F]Florbetapir
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
FTLD, Progressive Supranuclear Palsy (PSP)
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary…
- Conditions
- FTLD, Progressive Supranuclear Palsy (PSP), Frontotemporal Dementia (FTD), Corticobasal Degeneration (CBD)
- Trial name
- ARTFL (NCT02365922)
- Where
- 17 sites in United States, Canada
- Volunteers
- 1,489 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Alzheimer Disease, Progressive Supranuclear Palsy
Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls
This is an experimental medicine study to evaluate the kinetics of cerebrospinal fluid (CSF) biomarkers in subjects with Alzheimer's disease (AD) or progressive supranuclear palsy (PSP) compared to healthy controls using a heavy…
- Trial name
- NCT01348061
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- KineMed
Alzheimer Disease, Progressive Supranuclear Palsy
Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases
Tau protein has been identified as one of the key pathological features of Tau proteinopathies, such as Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD).
- Conditions
- Alzheimer Disease, Progressive Supranuclear Palsy, Frontotemporal Dementia
- Trial name
- NCT05260151
- Where
- China
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Progressive Supranuclear Palsy, Corticobasal Degeneration
Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration
Drug therapy of atypical parkinsonism is generally considered either ineffective or minimal 1. Therefore, there is an urgent need to find alternative therapies to treat atypical parkinsonian disorders.
- Conditions
- Progressive Supranuclear Palsy, Corticobasal Degeneration, Parkinsonism
- Trial name
- NCT01174771
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Parkinson Disease, Progressive Supranuclear Palsy
Oxford Study of Quantification in Parkinsonism
The OxQUIP (Oxford QUantification In Parkinsonism) study is recruiting patients with Parkinson's Disease and Progressive Supranuclear Palsy.
- Trial name
- OxQUIP (NCT04139551)
- Where
- United Kingdom
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Healthy Volunteers, Alzheimer Disease
Phase 1 Test-retest Evaluation of [18F]MNI-958 PET
The overall goal of this protocol is to evaluate [18F]MNI-958 also known as APN-0000455 or PM-PBB3, a tau targeted radiopharmaceutical.
- Conditions
- Healthy Volunteers, Alzheimer Disease, Progressive Supranuclear Palsy
- Trial name
- NCT03545789
- Testing
- [18F]MNI-958
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Invicro
Alzheimer's Disease, Cortical Basal Syndrome
18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls
This is an open-label study to evaluate the performance of a novel tau imaging ligand in up to 36 subjects (12 AD, 3 FTD, 3 PSP, 3 CBS, 3 VCI and 12 HV).
- Conditions
- Alzheimer's Disease, Cortical Basal Syndrome, Frontotemporal Dementia, Progressive Supranuclear Palsy
- Trial name
- NCT03625128
- Testing
- F-18
- Where
- Taiwan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration
PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK
Progressive Supranuclear Palsy (PSP), Cortico-Basal Degeneration (CBD) and Multiple System Atrophy (MSA) are degenerative brain conditions for which there are currently no curative treatments.
- Conditions
- Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration, Multiple System Atrophy (MSA)
- Trial name
- PROSPECT-M (NCT02778607)
- Where
- United Kingdom
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- University College, London